PUBLISHER: Inkwood Research | PRODUCT CODE: 1277623
PUBLISHER: Inkwood Research | PRODUCT CODE: 1277623
The global male infertility market is predicted to record a 4.53% CAGR during the forecast period from 2023 to 2032. Surging incidences of infertility, adoption of assisted reproductive technologies, and technological advancements boost the market growth globally.
Several significant factors drive the growth of the global male infertility market, including issues with sperm production or delivery, such as low sperm count, abnormal sperm function, or blockages, commonly cause male infertility. Additionally, illnesses, chronic health problems, injuries, lifestyle choices, and other factors contribute to male infertility.
The surging incidence of infertility and the adoption of assisted reproductive technologies (ART) are crucial in addressing male infertility challenges. Assisted reproductive technologies provide a viable solution for men facing infertility issues, offering higher success rates compared to medications. The widespread adoption of these technologies has increased pregnancy possibilities for infertile couples worldwide, contributing to the growth of the male infertility market.
The global male infertility market evaluation comprises a study of Asia-Pacific, North America, Europe, and Rest of World. Europe is estimated to dominate in terms of market share owing to the increased adoption of affordable therapies and devices, assisted reproductive technologies, and reimbursement coverage.
The global male infertility market is characterized by intense competition due to the presence of numerous companies. These companies strive to develop innovative products for infertility treatment, and regional players compete with established brands. Market players focus on conducting clinical trials, developing new products, and launching novel solutions to gain a competitive edge.
Leading market players include: CinnaGen Co, Endo International PLC, Caerus Biotech, EMD Serono Inc (Merck Serono), etc.